This federal Project Grant award for $772,501.00, awarded on May 1, 2024 by the Defense Health Agency, supports the University of Nebraska Medical Center's research project titled "BUTYRYLCHOLINESTERASE: AN OUTSTANDING DIAGNOSTIC AND DRUGGABLE BIOMARKER IN UVEAL MELANOMA." The project, funded under the Military Medical Research and Development program (CFDA 12.420), aims to advance research into butyrylcholinesterase as a diagnostic and therapeutic target for uveal melanoma, a rare and aggressive form of eye cancer. The University of Nebraska Medical Center, a division of the University of Nebraska, will carry out this 3-year research initiative through this federal grant award.
Generated 1/28/25, 7:50 AM